Journal article
SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients
Kidney360, Vol.3(1), pp.133-143
01/27/2022
DOI: 10.34067/KID.0005732021
PMID: 35368573
Abstract
Background: Morbidity and mortality associated with coronavirus disease 2019 (COVID-19) infection in kidney transplant recipients are high and early outpatient interventions to prevent progression to severe disease are needed. SARS-CoV-2 neutralizing mAbs, including bamlanivimab and casirivimab-imdevimab, received emergency use authorization in the United States in November 2020 for treatment of mild to moderate COVID-19 disease.
Methods: We performed a retrospective analysis of 27 kidney transplant recipients diagnosed with COVID-19 between July 2020 and February 2021 who were treated with bamlanivimab or casirivimab-imdevimab and immunosuppression reduction. We additionally identified 13 kidney transplant recipients with COVID-19 who had mild to moderate disease at presentation, who did not receive mAbs, and had SARS-CoV-2 serology testing available.
Results: There were no deaths or graft failures in either group. Both infusions were well tolerated. Four of the 27 patients treated with mAbs required hospitalization due to COVID-19. Four of 13 patients who did not receive mAbs required hospitalization due to COVID-19. Patients who received mAbs demonstrated measurable anti-SARS-CoV-2 IgG with angiotensin-converting enzyme 2 (ACE2) receptor blocking activity at the highest level detectable at 90 days postinfusion, whereas ACE2 blocking activity acquired from natural immunity in the mAb-untreated group was weak.
Conclusions: Bamlanivimab and casirivimab-imdevimab combined with immunosuppression reduction were well tolerated and associated with favorable clinical outcomes in kidney transplant recipients diagnosed with mild to moderate COVID-19.
Details
- Title: Subtitle
- SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients
- Creators
- Aileen X. Wang - Stanford MedicineStephan Busque - Stanford MedicineJamie Kuo - Stanford Health CareUpinder Singh - Stanford MedicineKatharina Röeltgen - Stanford University School of MedicineBenjamin A. Pinsky - Stanford MedicineJohn D. Scandling - Stanford MedicineColin R. Lenihan - Stanford MedicineGlenn M. Chertow - Stanford University
- Resource Type
- Journal article
- Publication Details
- Kidney360, Vol.3(1), pp.133-143
- DOI
- 10.34067/KID.0005732021
- PMID
- 35368573
- NLM abbreviation
- Kidney360
- ISSN
- 2641-7650
- eISSN
- 2641-7650
- Number of pages
- 11
- Grant note
- Astellas Pharma US (http://data.elsevier.com/vocabulary/SciValFunders/100004324) R25AI147369; 1R25Al147369-01 / National Institute of Allergy and Infectious Diseases (http://data.elsevier.com/vocabulary/SciValFunders/100000060) Division of Intramural Research, National Institute of Allergy and Infectious Diseases (http://data.elsevier.com/vocabulary/SciValFunders/100006492) CareDx (http://data.elsevier.com/vocabulary/SciValFunders/100016477)
- Language
- English
- Date published
- 01/27/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985244558102771
Metrics
2 Record Views